PARP inhibitors have established themselves as part of the treatment armamentarium against ovarian cancer, BRCA-mutant breast cancer, BRCA-mutant pancreatic cancer and HRD-deficient prostate cancer. The gene discussed is PARP1; the disease is familial pancreatic carcinoma.